The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab

Sponsor
Evangelismos Hospital
Study ID
NCT05896943
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ustekinumab — DRUG
    Patients with ulcerative colitis treated with ustekinumab

Study Details

The investigators hope that the present study will highlight new transcriptomic prognostic markers of response to Ustekinumab with the ultimate goal of individualizing treatment and making a more targeted selection of UC patients who will benefit from this biological agent.

Key Dates

Start date
Apr 1, 2022
Status verified
Mar 2025
Primary completion
Oct 31, 2023
Completion
Sep 25, 2024

Study Design

Enrollment
38 participants (actual)

Arms

  • Arm: Ulcerative colitis patients treated with ustekinumab
    Patients with Ulcerative Colitis treated with ustekinumab

Primary Outcome Measure

the rate of clinical remission [ Time Frame: 6 months ]

Related Studies